R&D channel feed

An un­ortho­dox pro­pos­al for Bio­gen's Medicare-man­dat­ed Aduhelm tri­al

4 years ago
Pharma

EQRx adds ar­mor to its dis­count check­point in­hibitor sub­mis­sion, nail­ing sur­vival mark in key study

4 years ago

No stranger to head­winds, blue­bird runs in­to two PDU­FA de­lays un­re­lat­ed to new safe­ty is­sues

4 years ago
FDA+

FDA or­ders DMD tri­al halt, rais­ing ques­tions about a whole class of promis­ing drugs

4 years ago
Cell/Gene Tx

Tiny biotech ham­mered as lead drug fails a key PhII study

4 years ago

Ten months af­ter dev­as­tat­ing fail­ure, Roche says it sees path for­ward for Hunt­ing­ton’s drug

4 years ago

#JPM22: High­lights for the year ahead in on­col­o­gy R&D — What's hot, what's not?

4 years ago

#JPM22 - The gene edit­ing rev­o­lu­tion: Now it's time for hu­man da­ta to de­fine a fast-chang­ing field

4 years ago

Covid-19 man­u­fac­tur­ing roundup: NY biotech primed to be­come Im­mu­ni­ty­Bio's drug sub­stance gold­mine; Illi­nois set to meet de­mand for at-home tests

4 years ago

De­nal­i's Alzheimer's drug faces set­back at the FDA af­ter agency slaps clin­i­cal hold on hu­man tri­al start

4 years ago

With new Omi­cron da­ta, Ada­gio halts tri­als for vaunt­ed Covid an­ti­body but sees a path ahead

4 years ago
Coronavirus

Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

4 years ago

#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

4 years ago

As Abec­ma sales take off, Bris­tol My­ers and 2sev­en­ty scrap a fol­low-up CAR-T

4 years ago

Dai­ichi Sankyo shuts down Plexxikon sub­sidiary to stream­line En­her­tu, ADC de­vel­op­ment

4 years ago
People
Pharma

Ex­clu­sive: Bio­gen pres­i­dent fears CMS will fi­nal­ize re­stric­tive cov­er­age de­ci­sion for Aduhelm, preps plans to flood NCD with com­ments

4 years ago
Pharma

Sarep­ta's sec­ond shot at show­ing its Duchenne gene ther­a­py de­liv­ers pos­i­tive da­ta but un­der­whelms — shares tum­ble

4 years ago
Cell/Gene Tx

7 block­busters: An­a­lysts spot­light 2022’s crop of drugs most like­ly to win top mar­ket­ing sta­tus — 2 drugs dom­i­nate

4 years ago
Pharma

Take­da kicks off JPM week with M&A — buy­ing out an­oth­er gam­ma/delta spin­out and div­ing in­to a new ‘swim lane’

4 years ago
Deals

How durable is durable? Bio­Marin gears up to bring he­mo­phil­ia A gene ther­a­py to FDA again with 2-year da­ta

4 years ago
Cell/Gene Tx

Fu­ji­film Diosynth adds on at its NC hub, bol­ster­ing lab space with plans to bring on 145 new jobs

4 years ago
Manufacturing

Ali­gos crum­bles af­ter ax­ing lead as­set, as an­a­lysts rue an­oth­er flop in 'beat­en-down' sec­tor

4 years ago

Sanofi, Ex­sci­en­tia ink the next AI megadeal, sign­ing terms on a $100M up­front pact with up to 15 drugs on the line

4 years ago
Deals

No­vo Hold­ings picks up in­jecta­bles CD­MO in push for sin­gle-use man­u­fac­tur­ing tech

4 years ago
Manufacturing
First page Previous page 149150151152153154155 Next page Last page
A service from the Financial Times